Algiax Pharmaceuticals Announces New Executive Team and Clinical Trial Plan for Lead Candidate AP-325
Algiax Pharmaceuticals Appoints Dr. Ingo Lehrke and Dr. Guido Koopmans as CEO and CSO. A Proof-of-Concept Study for Neuropathic Pain…
Pharmaceuticals, Biotechnology and Life Sciences
Algiax Pharmaceuticals Appoints Dr. Ingo Lehrke and Dr. Guido Koopmans as CEO and CSO. A Proof-of-Concept Study for Neuropathic Pain…
Company to Develop Gene Editing Therapies to Permanently Reduce Risk of Coronary Artery Disease in Adults Announces Key Licensing Agreements…
DUBLIN–(BUSINESS WIRE)–The “Active Pharmaceutical Ingredients (API) Global Market – Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering. According…
DUBLIN–(BUSINESS WIRE)–The “Active Pharmaceutical Ingredients (API) Global Market – Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering. According…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…
Proceeds will support ongoing clinical evaluation of HepaStem® in ACLF and launch of a clinical trial in late stage NASH…
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and…
In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond…
MARIETTA, Ohio–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AAGP?src=hash" target="_blank"gt;#AAGPlt;/agt;–ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) has been requested by OTC Markets Group…
Move reinforces strategic focus on core businesses Consolidated non-GAAP adjusted EBITDA margin expected to increase to approximately 45% from its…